NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, published by SAGE PUBLICATIONS INC, is a premier academic journal dedicated to advancing the understanding of mental health issues and neurological disorders in the aging population. With an established presence since 1988, this journal stands out in the fields of Geriatrics, Gerontology, Neurology, and Psychiatry, currently positioned in the Q2 category based on 2023 metrics, reflecting its influence and academic rigor. The journal is indexed in major databases and is highly regarded for its contributions, as evidenced by its strong Scopus rankings. It serves as an essential resource for researchers, clinicians, and students, offering insightful articles that explore the complex interplay between aging, mental health, and neurological conditions. Although it does not provide open access, it continues to be a vital source of scholarly knowledge for those dedicated to enhancing the well-being of the elderly population.

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, published by Lippincott Williams & Wilkins, is a pivotal journal for advancing knowledge in the fields of clinical psychology, geriatric medicine, and psychiatry. With a history spanning from 1987 to 2024, this journal provides a comprehensive platform for researchers and clinicians to disseminate significant findings related to Alzheimer's disease and associated cognitive disorders. Ranked within the second and third quartiles in various categories, including clinical psychology and geriatrics, it retains a solid academic reputation, indicated by its diverse Scopus rankings, such as #137 in Clinical Psychology and #20 in Nursing & Gerontology. Although it does not offer open access, the journal is recognized for its commitment to peer-reviewed research, making it a valuable resource for professionals and students alike, aiming to stay abreast of the latest developments and evidence-based practices in Alzheimer’s and associated conditions.

Annals of Neurosciences, published by SAGE Publications Ltd, is a distinguished journal that serves the vibrant field of neuroscience. With an ISSN of 0972-7531 and E-ISSN 0976-3260, it has been a significant platform for advancing knowledge in various aspects of neuroscience since its inception. The journal, positioned in the Q3 category in the realm of neurosciences (miscellaneous) as of 2023, aims to bridge the gap between basic research and clinical practices, providing a comprehensive forum for the dissemination of innovative research, reviews, and insights within the field. With a convergence period from 2011 to 2024, it continually emphasizes the importance of interdisciplinary approaches in understanding neural mechanisms and their implications for mental health and neurological disorders. The journal's open access options ensure that research findings are widely available, fostering collaboration and dialogue among researchers, professionals, and students globally. Located in London, England, the Annals of Neurosciences stands out as an essential publication for those aiming to stay at the forefront of neuroscience research and application.

BMC NEUROSCIENCE is a prominent open access journal dedicated to the dissemination of high-quality research within the dynamic and rapidly evolving field of neuroscience. Published by BMC, a well-respected leader in open access publishing, this journal facilitates the free exchange of knowledge since its inception in 2000. With the ISSN 1471-2202, BMC NEUROSCIENCE aims to address the diverse interests of the neuroscience community by covering a broad spectrum of topics, ranging from cellular and molecular neuroscience to general neurological studies, thus appealing to researchers, professionals, and students alike. Although it currently holds a Q4 ranking in Cellular and Molecular Neuroscience and a Q3 rank in miscellaneous Neuroscience categories, its commitment to advancing the understanding of brain function and disorders remains steadfast. The journal features a user-friendly Open Access model, ensuring that critical research findings are readily accessible to everyone, fostering collaboration and innovation in the field. As the journal continues to evolve towards its convergence years of 2024, it aspires to enhance its impact and global reach, making it a valuable resource for anyone interested in advancing neuroscience research.

Dementia and Geriatric Cognitive Disorders Extra, published by KARGER in Switzerland, is an esteemed open-access journal dedicated to advancing research in the fields of cognitive neuroscience, geriatrics, and psychiatry. With a commitment to disseminating high-quality research since its inception in 2011, the journal plays a crucial role in highlighting innovative studies that address cognitive disorders associated with aging. As an open-access platform, it ensures that findings are accessible to a global audience, fostering collaboration and knowledge-sharing among researchers, professionals, and students alike. The journal has been recognized for its impact in Cognitive Neuroscience and Psychiatry and Mental Health, achieving a Q3 category ranking, indicating its reputable standing within these fields. By delivering cutting-edge insights and promoting interdisciplinary approaches, Dementia and Geriatric Cognitive Disorders Extra is instrumental in enhancing understanding and treatment of cognitive decline, making it a vital resource for anyone engaged in the study of aging and cognitive health.

Alzheimers & Dementia is a premier journal published by WILEY that focuses on the latest advancements in understanding, diagnosing, and treating Alzheimer's disease and other dementias. With an ISSN of 1552-5260 and an E-ISSN of 1552-5279, this influential journal boasts a commendable impact factor and ranks in the Q1 category across several disciplines, including *Cellular and Molecular Neuroscience*, *Geriatrics and Gerontology*, and *Neurology (Clinical)*. By publishing cutting-edge research, systematic reviews, and innovative clinical trials, Alzheimers & Dementia aims to bridge the gap between basic neuroscience and clinical practice, offering valuable insights into the etiology, epidemiology, and management of dementia-related disorders. The journal is hosted in the United States and operates under a balanced access model, providing essential resources for researchers, healthcare professionals, and students dedicated to tackling the challenges posed by these neurodegenerative diseases. Available online, it plays a pivotal role in shaping current and future research directions in the vibrant field of dementia studies.

The GERONTOLOGIST, published by Oxford University Press Inc, is a premier journal in the field of geriatrics and gerontology, with a distinguished history since its inception in 1961. This esteemed journal stands out with its impressive Q1 rankings in prominent categories, including Geriatrics and Gerontology, reflecting its vital role in disseminating innovative research and advancing knowledge within these critical disciplines. With an impact factor that ranks it among the top journals in both Nursing Gerontology and Medicine, the GERONTOLOGIST serves as a key resource for researchers, professionals, and students dedicated to enhancing the health and well-being of older adults. Although it operates under a traditional access model, the journal remains committed to publishing cutting-edge studies that address the complexities of aging and inform evidence-based practices. By fostering a rich dialogue among scholars and practitioners, the GERONTOLOGIST is instrumental in shaping the future of gerontological research and policy.

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, published by WILEY, stands at the forefront of research in the fields of neurology and psychiatry. As an Open Access journal since 2015, it fosters transparency and accessibility in sharing critical knowledge pertaining to the diagnosis, assessment, and monitoring of Alzheimer’s disease and related dementias. With an impressive impact factor reflected in its Q1 rankings in both Neurology (Clinical) and Psychiatry and Mental Health, this journal is recognized for its significant contribution to advancing understanding and improving clinical practices, as evidenced by its Scopus rankings in the top percentiles. Researchers, healthcare professionals, and students are encouraged to engage with the latest findings and methodologies that shape the future of dementia care, enhancing both patient outcomes and the scientific community's response to this pressing health challenge. With its headquarters located in Hoboken, NJ, this journal is a pivotal platform for disseminating high-quality, peer-reviewed research that strives to combat one of the most challenging areas in medicine today.